Abstract 860
Background
Breast cancer is a major public health problem among women. The use of phytoestrogens like Resveratrol (RSV) has been emerged as a promising chemopreventive and chemotherapeutic agent against breast cancer. However, its effect is reported to be variable according to the administered dose. So this study investigated the underlying mechanisms to the dual action of RSV on estrogen expressing type of breast carcinoma cells (MCF-7).
Methods
MCF-7 cells treated with different low and high doses of RSV and the consequent cytotoxicity, cell cycle, oxidative, angiogenic and inflammatory responses of the cells were evaluated. The autophagic behavior of MCF-7 cells was assessed by RSV combination with autophagic inhibitor (cloroquine). The effect of the combination on cell survival, autophaghic markers expression along with acridine orange staining and cell apoptosis was determined.
Results
Compared to the higher concentration, low dose of RSV (10 µg/ml) exhibited significant anti-survival effect accompanied with cell accumulation at G0/G1phase, higher MDA and VEGF secretion. Concerning the higher doses of RSV (30 and 50 µg/ml), more cells accumulated at S and G2/M phases, and significantly higher levels of GSH, COX-2, PGE2 and nitrate secretion were observed. Autophagic inhibition of RSV exhibited significant acidic lysosomal staining, anti-survival and pro-apoptotic effects on breast carcinoma cells. The combination of low RSV concentration (10 µg/ml) with autophagic inhibitor caused significant decrease in Beclin-1, LC3-B, BCl-2 and MCl-1 expressions, while higher doses of RSV (30 and 50 µg/ml) combination induced Beclin-1, BCl-2 and MCl-1 but reduced LC3-B expressions compared with the single treatment of RSV.
Conclusions
The cytotoxic effect of RSV depends on the autophagic response of breast carcinoma cells in relation to the applied dose.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3887 - First Real Life Data on Durvalumab after definitive concomitant ChemoRadiotherapy (cCRT) in unresectable Stage (St) III Non-Small Cell Lung Cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) Temporary Authorization of Use (ATU)
Presenter: Virginie Avrillon
Session: Poster Display session 1
Resources:
Abstract
682 - EGFR Inhibitor Versus Chemotherapy as Adjuvant Treatment for Locally-advanced EGFR-mutant Non-Small Cell Lung Cancer
Presenter: Peng Xie
Session: Poster Display session 1
Resources:
Abstract
2509 - Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: interim analysis of a Phase IIIb, multi-national, open-label study
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3300 - First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
Presenter: Daniel SW Tan
Session: Poster Display session 1
Resources:
Abstract
2653 - A combined analysis of two Phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3663 - Impact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients
Presenter: Xiaohong Wang
Session: Poster Display session 1
Resources:
Abstract
5921 - Definition of an afatinib trough concentration threshold in the treatment of NSCLC
Presenter: Stephane Bouchet
Session: Poster Display session 1
Resources:
Abstract
2852 - A Phase Ib Trial of Neoadjuvant Chemoradiotherapy and Durvalumab(MEDI4736) for Potentially Resectable stage III Non-Small Cell Lung Cancer (NSCLC)
Presenter: Beung chul AHN
Session: Poster Display session 1
Resources:
Abstract
3273 - Low expression of Notch1 and combined Notch1/HES1 are associated with adverse survival factor for limited stage small cell lung cancer
Presenter: Jinsoo Lee
Session: Poster Display session 1
Resources:
Abstract
5141 - Mutational profiling of tumor tissue and sequential plasma illustrates emergent clones during treatment in late stage small cell lung cancer (SCLC)
Presenter: Stephanie Yaung
Session: Poster Display session 1
Resources:
Abstract